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Rationale: The purpose of this study was to investigate the clinical efficacy and safety of a
fixed-dose combination of mometasone furoate/formoterol fumarate (MF/F) administered via
a metered-dose inhaler in subjects with moderate-to-very severe chronic obstructive pulmonary
disease (COPD).
Methods: This multicenter, double-blind, placebo-controlled trial had a 26-week treatment
period and a 26-week safety extension. Subjects (n = 1196), at least 40 years old, were current or
ex-smokers randomized to twice-daily inhaled MF/F 400/10 µg, MF/F 200/10 µg, MF 400 µg,
F 10 µg, or placebo. The trial’s co-primary endpoints were mean changes from baseline, as area
under the curve (AUC), in forced expiratory volume (FEV1) over 0–12 hours (AUC0−12 h FEV1)
with MF/F versus MF, and in morning (AM) pre-dose (trough) FEV1 with MF/F versus F after
13 weeks of treatment. Key secondary endpoints were the effects of MF/F on respiratory health
status using the Saint George’s Respiratory Questionnaire (SGRQ), symptom-free nights, partly
stable COPD at 26 weeks, and time to first COPD exacerbation.
Results: The largest improvements in AUC0−12 h FEV1 were observed with MF/F 400/10 µg and
MF/F 200/10 µg. Serial spirometry results demonstrated that bronchodilator effects with MF/F
occurred rapidly (within 5 minutes), persisted for 12 hours after dosing, and were sustained over
the 26-week treatment period. Similar findings were observed for AM pre-dose FEV1, for which
effects were further investigated, excluding subjects whose AM FEV1 data were incorrectly
collected after 2 days from the last dose of study treatment. Improvements in SGRQ scores
surpassed the minimum clinically important difference of more than four units with both MF/F
treatments. At 26 weeks, no notable between-treatment differences in the occurrence and nature
of adverse events (AEs) were reported. No unexpected AEs were observed. Overall, 90 subjects
reported AEs considered to be treatment-related, the most common of which were lenticular
opacities, dysphonia, and oral candidiasis.
Discussion: In conclusion, MF/F treatments improved lung function and respiratory health
status, reduced exacerbations, and were well tolerated in subjects with moderate-to-very severe
COPD.
Keywords: COPD, FEV1, spirometry, exacerbation, inhaled corticosteroid, bronchodilator

Introduction
Chronic obstructive pulmonary disease (COPD) is common in adults, with COPD
of at least moderate severity affecting an estimated 10% of the world’s population.1
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COPD is the third leading cause of death in the US, and
is expected to be the third leading cause of death worldwide by 2020.1,2 The burden of COPD on society is large
(US$50 billion estimated direct and indirect costs in the US
in 2010) and growing. It also poses a tremendous burden on
people afflicted with the disease.
COPD is characterized by a progressive decline in lung
function and slowly progressing symptoms,3 as described in
COPD guidelines. The Global Initiative for Chronic Obstructive Lung Disease (GOLD)4 and a joint statement of the
American Thoracic Society (ATS) and European Respiratory
Society (ERS)3 provide guidelines on the diagnosis and management of stable COPD. All COPD grades are associated
with a postbronchodilator forced expiratory volume (FEV)
to forced vital capacity (FVC) ratio #0.70, indicating that
airway obstruction is only partially reversible. These guidelines define four grades of COPD that stratify severity based
on spirometry measurement of FEV in 1 second (FEV1) as a
percentage of that predicted. However, many patients with
COPD respond significantly, albeit not fully, in response to
a bronchodilator.5,6 Although COPD cannot be cured, it is
not an untreatable disease.
The GOLD guidelines recommend scheduled maintenance treatment with long-acting bronchodilators for patients
with moderate COPD (FEV1 ,80% and $50% predicted),
and also recommend the addition of an inhaled corticosteroid
(ICS) to long-acting bronchodilator therapy for patients with
severe COPD (FEV1 ,50% predicted) and repeated exacerbations.4 In 2011, an official statement of the American
College of Physicians (ACP), American College of Chest
Physicians (ACCP), ATS, and ERS raised the FEV1 threshold from ,50% to ,60% predicted for the recommendation
of adding an ICS to the bronchodilator regimen of COPD
patients who have frequent exacerbations.7 The ACP/ACCP/
ATS/ERS guidelines also state that pharmacologic combinations (eg, long-acting β2-agonists [LABA] and ICS) may
be used by symptomatic patients with stable COPD and an
FEV1 ,60% predicted.7
Measurement of FEV1 is a standard endpoint that has
been frequently used in pivotal trials evaluating potential
COPD treatments.8–11 Other important measures of therapeutic efficacy in COPD treatment studies are patient-centered
outcomes, such as improvement of symptoms, exercise
tolerance, and/or quality of life. Furthermore, the ability of a
COPD treatment(s) to reduce exacerbations, especially those
requiring hospitalization, is another widely used endpoint to
measure therapeutic value. It is important to note that spirometric responses to treatment, such as improvement in FEV1,
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do not always correlate with improvements in symptoms, or
vice versa.7 This supports a rationale for evaluating multiple
efficacy endpoints in clinical trials of COPD treatments.
Fixed-dose ICS/LABA combination inhalers are now
available worldwide. Three ICS/LABA combinations are
approved for the treatment of COPD: fluticasone propionate/
salmeterol (FPS), budesonide/formoterol (BF), and beclo
methasone dipropionate/formoterol. FPS8,9,12,13 and BF11,14
have been shown to improve lung function and health status
in patients with COPD. Although the existing ICS/LABA
components and fixed-dose combinations (FDC) are similar, they are not identical (eg, differences in bronchodilator
onset15 and ICS bioavailability16). Accordingly, a new FDC
with a different ICS component (mometasone) may bring
different features and possible benefits to the maintenance
treatment of patients with COPD. Mometasone furoate
(MF) and formoterol (F) have been investigated in multiple
pharmacologic and clinical studies. MF is distinguished
by its high glucocorticoid receptor affinity and potent antiinflammatory activity, in addition to its low systemic bioavailability.17,18 Additionally, F is distinguished by the rapid
onset and sustained duration of its bronchodilator effect.19
MF administered via a dry powder inhaler (DPI) has been
investigated in COPD.20 F-DPI has been investigated21,22
and approved for use in COPD. Combined MF/F has been
investigated23–26 and is approved for treatment of patients
with asthma, but has yet to be evaluated for the maintenance
treatment of patients with COPD.
The objective of the present study was to assess the clinical efficacy and safety of two doses of MF/F metered dose
inhaler (MDI) daily: 400/10 µg BID and 200/10 µg BID
versus the individual components or placebo in adult subjects
with moderate-to-very severe COPD.

Methods
Patients
Included subjects were males or females $40 years old
with FEV1/FVC #0.70, with a post-bronchodilator FEV1
of 25%–60% predicted. Additional inclusion criteria
were: symptoms of COPD (eg, chronic cough and sputum
production not attributable to another disease) for at least
24 months prior to enrollment; current or ex-smokers
with $10 pack/year history; no use of parenteral steroids,
oral steroids, or antibiotics within 4 weeks prior to screening;
and clinically acceptable laboratory tests at screening. Female
subjects of childbearing potential were required to use a medically acceptable, adequate form of birth control. Subjects
were excluded if they had a current diagnosis of asthma,
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e xhibited marked bronchodilator reversibility (increase in
FEV1 $400 mL) versus baseline pre-bronchodilator FEV1,
had a COPD exacerbation within 4 weeks prior to randomization, or required long-term administration of supplemental
oxygen (.15 hours/day). Additional exclusion criteria were
a history of: lung cancer; alpha-1-antitrypsin deficiency;
previous lung surgery; cataract extractions in both eyes;
glaucoma or intraocular pressure $22 mmHg in either eye; or
the presence of clinically significant medical illness(es) that,
in the opinion of the principal investigator, could interfere
with the study.

Study design
This was a randomized, placebo-controlled, double-blind,
double-dummy, multicenter study (ClinicalTrials.gov
identifier: NCT00383721) of MF/F 400/10 µg BID and
MF/F 200/10 µg BID compared with MF 400 µg BID and
F 10 µg BID in adults with moderate-to-very severe COPD.
Total dose was delivered after two inhalations BID of the
following actuated doses: MF/F 200/5 µg, MF/F 100/5 µg,
MF 200 µg, F 5 µg, or placebo. The study was conducted
from 2007 to 2010 at 164 centers in North, Central, and South
America, Europe, Africa, and Asia. All centers conformed to
good clinical practice and to the study protocol. All centers
had the protocol approved by an institutional review board
and independent ethics committee. Informed consent was
obtained from each subject. All subjects completed a 2-week
washout/run-in period, in which previous long-acting COPD
treatments (LABA, ICS, LABA/ICS FDC, or long-acting
anticholinergic [eg, tiotropium]) were discontinued and substituted with an open-label, short-acting β2-agonist (SABA)/
short-acting anticholinergic combination.
At baseline, subjects were randomized in a 1:1:1:1:1 ratio
to 26 weeks of double-blind treatment with MF/F 400/10 µg
BID, MF/F 200/10 µg BID, MF 400 µg BID, F 10 µg BID,
or placebo. Comparisons of MF 400 µg and placebo were
included, since the clinical effects of the MF-MDI formulation used in this study have not been evaluated previously. All
inhalers were MDIs. The active and placebo MF/F and MF
inhalers were identical in appearance, as were the active and
placebo F inhalers. Spacers were not used in this study.
Efficacy and safety were evaluated over 6 months in the
active treatment and placebo groups. The placebo subjects
were discontinued from the trial after 6 months, owing
to concerns about placebo treatment for a longer period.
Seventy-five percent of subjects in each active treatment
group were randomly selected to participate in a 26-week
safety extension, which began after the initial 26-week
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treatment period. During the safety extension, FEV1, peak
expiratory flow (PEF), and adverse event data, as well
as additional data (eg, patient diary, electrocardiogram,
COPD stability score, exacerbation evaluation, treatment adherence, and eye examination) were assessed to
monitor efficacy and to assure subject safety. In addition,
hypothalamic-pituitary-adrenal (HPA) axis and bone mineral
density (BMD) data were collected at selected centers at the
end of the safety extension (week 52).

Efficacy assessments
This study was designed to evaluate the contribution of
each component of a combination inhaler (mometasone plus
formoterol formulation) to COPD maintenance treatment.
The co-primary endpoints were: 1) MF/F 400/10 µg compared with MF 400 µg for FEV1 area under the curve from
0 to 12 hours post-dose (AUC0–12 h) at the week 13 endpoint
(last observation carried forward [LOCF]) to assess the added
benefit of F on bronchodilation, and 2) MF/F 400/10 µg
and MF/F 200/10 µg compared with F 10 µg for AM predose (trough) FEV1 at the week 13 endpoint to assess the
added benefit of MF on trough FEV1. Secondary efficacy
endpoints included assessment of changes from baseline in
FEV1 AUC0–12 h at day 1, weeks 1, 13, 26, and the 26-week
endpoint (LOCF), as well as assessment of changes from
baseline in trough FEV1 at each visit and at the 26-week
endpoint. Serial spirometry tests were performed at day 1,
as well as at weeks 1, 13, and 26, which included measuring
the pre-dose FEV1 30 minutes and immediately prior to the
AM dose, and then at 5, 15, 30 minutes, and 1, 2, 3, 4, 6, 8,
10, 11, and 12 hours post-dose.
The key secondary efficacy endpoints evaluated for the
26-week treatment period were respiratory health status
scores, assessed with the St George’s Respiratory Questionnaire (SGRQ);27 COPD symptom-free nights (combined
score of 0 upon awakening for wheezing, cough, and difficulty breathing); and, as defined below, partly stable
COPD, and time to first mild, moderate, or severe COPD
exacerbation. The SGRQ consists of three component scores
(symptoms, activity, impact) and a total score, each of which
ranges from 0–100. The better SGRQ scores have a lower
numeric value. A four-point difference from baseline or
placebo is considered the minimum clinically important
difference (MCID).28,29 Partly stable COPD was defined
as no use of oral steroid rescue medication; no AM or PM
COPD weekly average symptom score .2 during at least 7
of 8 weeks; no moderate or severe COPD exacerbations; no
unscheduled visits due to COPD worsenings; and/or no study
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discontinuation due to treatment failure or treatment-related
adverse event (AE).
COPD exacerbations were assessed during the screening
and treatment periods, as well as during the 26-week safety
extension, and were categorized as mild, moderate, or severe.
A mild exacerbation was defined as a clinically judged
deterioration of COPD symptoms (managed with increased
short-acting bronchodilator use: $12 inhalations/day of
SABA/short-acting anticholinergic, or $2 nebulized treatments/day of 2.5 mg SABA/short-acting anticholinergic)
on any two consecutive days. A moderate exacerbation was
defined as a clinically judged deterioration of COPD with an
acute change in symptoms that required antibiotic and/or oral
steroid treatment for lower airway disease. A severe exacerbation was defined as a deterioration of COPD that resulted
in emergency treatment or hospitalization due to COPD.
Data were analyzed for the time to first mild, moderate, or
severe COPD exacerbation and for the time to first moderate
or severe COPD exacerbation, excluding mild events.

Safety and e-diary assessments
Safety assessments included monitoring of treatmentemergent AEs (ie, those that occurred during randomized
treatment), vital signs, oropharyngeal changes, and forearm
bruising. AEs were monitored by investigators and may have
included the onset of new illness and the exacerbation of
pre-existing conditions (eg, COPD). Laboratory assessments,
electrocardiography, and ophthalmologic examinations were
conducted at screening and at final visit. Chylack Incorporated (Duxbury, MA) provided guidance for ocular examinations and online training to ophthalmologists for Lens
Opacities Classification System III (LOCS III) certification.
Measurements of BMD and 24-hour plasma cortisol were
conducted at selected centers. Dual-energy X-ray absorptiometry (DXA) scans of the lumbar spine, left total femur,
and femoral neck were obtained from a subgroup of subjects
at selected centers. CCBR-Synarc (Portland, OR) provided
centralized analysis of the DXA scans, project management
related to DXA, and instrument quality control.
Each patient was given an e-diary (CareFusion Germany
234 GmbH, Höchberg, Germany) with a built-in spirometer
to capture PEF, and a self-contained device to record information about medication use, nocturnal awakenings, COPD
symptoms, and stability. COPD stability was evaluated with
5- or 6-point scale (0 = best, 4 to 5 = worst), measuring
breathlessness, mucus production, chest tightness, cough,
interference with personal care, and interference with outdoor
activities. All of the scores, except coughing, were based on
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5-point scales from 0 to 4. The coughing score was based
on a 6-point scale from 0 to 5. Investigators or designated
personnel at each site reviewed and downloaded subjects’
e-diary entries.

Statistical analyses
Efficacy analyses and safety summaries were based on the
intent-to-treat principle for all randomized subjects, with at
least some follow-up information provided. Subjects who
discontinued early were not replaced, and AEs occurring
up to 30 days after study completion or discontinuation
were reported. The target sample size was 1000 subjects
(200 subjects per treatment group). It was predetermined that
this sample size would be sufficient to detect a difference of
1.2 L/hour between MF/F 400/10 µg BID and MF 400 µg
BID (in change from baseline FEV1 AUC0–12 h) with 91%
power and a two-sided alpha level of 5% significance, assuming a pooled standard deviation of 3.6 L/hour. A 1.2 L/hour
AUC0–12 h converts to an average difference of 100 mL in
FEV1 across 12 hours. A difference of this magnitude is
considered clinically meaningful in subjects with this severity
of COPD. For AM pre-dose FEV1 at the week 13 endpoint,
the contribution of the MF 400 µg BID component was
expected to be 80 mL for a target treatment difference of
160 mL between MF/F 400/10 µg BID and placebo. This
treatment difference could be detected at 93% power with a
two-sided alpha level of 4.9%, assuming a pooled standard
deviation of 230 mL. The alpha level was adjusted to allow
for a nominal penalty of 0.1%.
The first co-primary efficacy endpoint was the mean
AUC0–12 h of the change in FEV1 from baseline to the week 13
endpoint, measuring the contribution of F 10 µg BID to the
combination. This analysis compared MF/F 400/10 µg BID
versus MF 400 µg BID, MF/F 400/10 µg BID versus placebo,
and F 10 µg BID versus placebo. All of these comparisons
had to be statistically significant at this dose level of MF/F
to assess successfully the F contribution at the overall alpha
level of 5%. The second co-primary efficacy endpoint for
the study was AM pre-dose FEV1 at the week 13 endpoint,
measuring the contribution of MF to the combination. This
analysis compared MF/F 400/10 µg BID versus F 10 µg BID,
MF/F 400/10 µg BID versus placebo, and MF 400 µg BID
versus placebo. All of these comparisons had to be statistically significant at this dose level of MF/F for the study to
be successful at an adjusted alpha level of 4.9%. The alpha
level was adjusted for an interim analysis to allow for a
penalty of 0.1%, preserving the overall alpha level of 5%
for the evaluation of the MF contribution. The contribution
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of MF to the MF/F combination was evaluated by analyzing
results in subjects whose AM pre-dose FEV1 measurements
were obtained in the protocol-defined time period, using
values considered as actual trough FEV1 values. In a second
analysis, performed post database lock, FEV1 evaluations
for each subject performed $2 days after the last dose of
treatment were excluded, and the week 13 AM pre-dose
FEV1 endpoint was recalculated using the last remaining
evaluation, as specified in the study protocol.
Responses for the above co-primary endpoints were
analyzed using an analysis of covariance (ANCOVA), extracting sources of variation due to treatment, country, smoking
status, and baseline. Pairwise comparisons were based on
least squares means from the model. After the significance of
co-primary endpoint analyses was confirmed, key secondary
endpoints were tested sequentially in order to control the
overall alpha level of 5%. If significance was not obtained
at any point in this process, then all subsequent comparisons
were considered to be descriptive. Changes from baseline
to the 26-week endpoint in SGRQ total score and COPD
symptom-free nights (AM symptoms) were analyzed using

the same ANCOVA as specified for the co-primary efficacy
variables. Baseline included AM symptoms over the last week
before the first dose. The proportion of subjects with partly
stable COPD at endpoint (the last 8 weeks of treatment) was
analyzed using the Cochran–Mantel–Haenszel test, controlling for smoking status. The time to first mild, moderate, or
severe COPD exacerbation and the time to first moderate or
severe COPD exacerbation were analyzed over the 26-week
treatment period and the 26-week safety extension using the
log-rank test for equality of survival (Kaplan–Meier) curves.
The effect of smoking status on the survival curves was examined for the 26-week treatment period. The data were analyzed
using SAS® software (v 9.1; SAS Institute, Cary, NC).

Results
Subject disposition
A total of 2936 subjects were screened and 1201 were
randomized (Figure 1). Five subjects were excluded from
primary efficacy and safety analyses because they were
enrolled at multiple sites. Thus, 1196 subjects were randomized for analysis, meeting the target sample size of

Screened
(n = 2936)

Randomized
(n = 1201)

Excluded from primary efficacy
and safety analysis (n = 5)

Randomized and analyzed for
primary efficacy and safety (n = 1196)

MF/F 400/10 µg BID
(n = 225)

MF/F 200/10 µg BID
(n = 239)

MF 400 µg BID
(n = 253)

F 10 µg BID
(n = 243)

Placebo
(n = 236)

Discontinued/reasons
(n = 34; 15%)
AE: 11 (5%)
Treatment failure: 1 (<1%)
Lost to follow-up: 0
Reasons unrelated to
treatment: 4 (2%)
Reasons related to
treatment: 5 (2%)
Noncompliance with
protocol: 7 (3%)
Did not meet protocol
eligibility: 5 (2%)
Administrative: 1 (<1%)

Discontinued/reasons
(n = 37; 15%)
AE: 5 (2%)
Treatment failure: 3 (1%)
Lost to follow-up: 0
Reasons unrelated to
treatment: 12 (5%)
Reasons related to
treatment: 3 (1%)
Noncompliance with
protocol: 5 (2%)
Did not meet protocol
eligibility: 6 (3%)
Administrative: 3 (1%)

Discontinued/reasons
(n = 51; 20%)
AE: 7 (3%)
Treatment failure: 3 (1%)
Lost to follow-up: 2 (1%)
Reasons unrelated to
treatment: 15 (6%)
Reasons related to
treatment: 6 (2%)
Noncompliance with
protocol: 4 (2%)
Did not meet protocol
eligibility: 11 (4%)
Administrative: 3 (1%)

Discontinued/reasons
(n = 50; 21%)
AE: 14 (6%)
Treatment failure: 4 (2%)
Lost to follow-up: 1 (<1%)
Reasons unrelated to
treatment: 10 (4%)
Reasons related to
treatment: 8 (3%)
Noncompliance with
protocol: 6 (2%)
Did not meet protocol
eligibility: 4 (2%)
Administrative: 3 (1%)

Discontinued/reasons
(n = 67; 28%)
AE: 13 (6%)
Treatment failure: 8 (3%)
Lost to follow-up: 4 (2%)
Reasons unrelated to
treatment: 11 (5%)
Reasons related to
treatment: 9 (4%)
Noncompliance with
protocol: 6 (3%)
Did not meet protocol
eligibility: 13 (6%)
Administrative: 3 (1%)

Completed 26 weeks
(n = 190; 84%)

Completed 26 weeks
(n = 202; 85%)

Completed 26 weeks
(n = 202; 80%)

Completed 26 weeks
(n = 193; 79%)

Completed 26 weeks
(n = 169; 72%)

Figure 1 Subject disposition.
Notes: Total doses were delivered after two inhalations BID of the following actuated doses: MF/F 200/5 µg, MF/F 100/5 µg, MF 200 µg, F 5 µg, or placebo.
Abbreviations: AE, adverse event; BID, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination formulation.
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1000 subjects. A total of 956 subjects (80%) completed
the 26-week double-blind treatment period, whereas
239 subjects (20%) discontinued from the study early.
The two most common reasons for discontinuation were
subjects not wanting to continue for reasons unrelated to
assigned study treatment (n = 52) and treatment-emergent
AEs (n = 50). In the placebo group, 67 subjects (28%) did
not complete the 26-week treatment period, including eight
treatment failures and four subjects lost to follow-up. In
the active treatment groups, 15% to 21% of subjects did
not complete the treatment period, with lower numbers of
treatment failures and losses to follow-up than in the placebo
group (Figure 1).

Subject demographics and disease
characteristics
Treatment groups were well-balanced regarding baseline
demographic characteristics with respect to age, race, and
sex (Table 1). Overall, 75% of subjects were males, about
70% were white, and the mean subject age was about
60 years. The MF/F 400/10 µg group had a higher proportion of current smokers (56%) than the other treatment
groups (range: 50%–53%), and a longer mean smoking
history (55 pack-years) than the other treatment groups
(range: 40–46 pack-years). Also, FEV1 reversibility at
screening tended to be higher in the F 10 µg group (10.37%)
than it was in the MF/F 400/10 µg and MF/F 200/10 µg
groups (8.69% and 8.47%, respectively). The mean postbronchodilator FEV1 at screening in all groups was between
38% and 40% predicted.

Co-primary efficacy variables
Treatment with MF/F resulted in significant improvements
in FEV1, which demonstrated the superiority of the FDC
versus the individual components of the combination. At
the week 13 endpoint, a significant difference of 126 mL
was observed in the mean change from baseline in FEV1
AUC0–12 h between MF/F 400/10 µg and MF 400 µg groups
(P , 0.001). MF/F 200/10 µg also significantly improved
FEV1 AUC0–12 h versus MF 400 µg (86 mL difference,
P , 0.001). A significant improvement of 74 mL was
reported for F 10 µg compared with placebo (P = 0.004)
(Figure 2). The effect of MF over 12 hours was evident in the
significantly greater improvement with MF 400 µg versus
placebo (35 mL, P = 0.038). The significant improvement
of FEV1 AUC0–12 h with MF/F 400/10 µg versus F 10 µg
(87 mL, P , 0.001) confirms the contribution of MF to
the combination.
Serial spirometric assessment of FEV1 post-dose at the
beginning (day 1) and end (week 26) of treatment identified
the rapid onset and sustained duration of bronchodilator
effects with MF/F (Figure 3). Significantly greater increases
in FEV1 occurred with both MF/F treatments compared with
MF at all time points, including 5 minutes after dosing, both
on day 1 (P , 0.001) and at week 26 (P # 0.035). These
results show the benefit of F in the combination formulation. The improvements in FEV1 with MF/F at the end of the
26-week treatment period demonstrated the added benefit of
the ICS component of the combination. Compared with F
10 µg, MF/F 400/10 µg had significantly greater increases
in FEV1 at all time points at week 26 (P # 0.016), whereas

Table 1 Subject demographics and clinical characteristics

Males, n (%)
Age (years), mean ± SD
Weight (kg), mean ± SD
White, n (%)
Black or African American,
n (%)
Asian, n (%)
Current smokers, n (%)
Ex-smokers, n (%)
Smoking history,
pack-years, mean ± SD
FEV1 reversibility,
mean % ± SD (mL)
Postbronchodilator FEV1
% predicted, mean ± SD

MF/F 400/10 μg BID
(n = 225)

MF/F 200/10 μg BID
(n = 239)

MF 400 μg BID
(n = 253)

F 10 μg BID
(n = 243)

Placebo
(n = 236)

168 (75)
59.2 ± 9.1
71.97 ± 19.85
156 (69)
3 (1)

175 (73)
60.1 ± 9.0
71.14 ± 17.41
164 (69)
10 (4)

197 (78)
60.5 ± 8.5
73.18 ± 19.14
177 (70)
4 (2)

182 (75)
59.7 ± 8.7
69.75 ± 18.89
167 (69)
4 (2)

178 (75)
58.8 ± 9.5
72.14 ± 21.49
155 (66)
8 (3)

30 (13)
127 (56)
98 (44)
54.8 ± 186.4

29 (12)
119 (50)
120 (50)
40.3 ± 26.2

36 (14)
134 (53)
118 (47)
41.1 ± 23.5

36 (15)
123 (51)
120 (49)
45.9 ± 79.1

34 (14)
120 (51)
115 (49)
43.5 ± 43.1

8.69 (102) ± 13.58

8.47 (100) ± 12.65

9.67 (121) ± 14.84

10.37 (121) ± 16.64

9.48 (113) ± 13.28

38.1 ± 10.8

38.7 ± 11.6

40.2 ± 11.7

38.2 ± 12.3

38.0 ± 11.5

Abbreviations: BID, twice daily; FEV1, forced expiratory volume in 1 second; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose
combination formulation.
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Figure 2 FEV1 AUC0–12 h at week 13 endpoint (LOCF).
Abbreviations: AUC0–12 h, area under the curve from 0 to 12 hours post-dose; BID, twice daily; FEV1, forced expiratory volume in 1 second; LOCF, last observation carried
forward; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination formulation.

MF/F 200/10 µg had significantly greater increases versus F
only at the 4- and 8-hour post-dose time points (P # 0.022)
Furthermore, as would be expected, both MF/F treatments
were superior to placebo (P # 0.019) at all time points
during serial spirometry assessments throughout the entire
treatment period.
Results with MF/F 400/10 µg and MF/F 200/10 µg versus
F 10 µg for the change from baseline in AM pre-dose (trough)
FEV1 at the week 13 endpoint indicate a contribution of MF to
the combination (Figure 4). However, the difference between
MF/F 400/10 µg and F 10 µg (49 mL) was marginally

B

A
Mean change from baseline (%)

significant for the pre-specified LOCF analysis (P = 0.062). In
analyses for observed cases (analyses based on observations
at specified time points, as opposed to observations carried
forward for endpoint analyses) at weeks 13 and 26, as well as
the week 26 endpoint, statistical significance was achieved,
with differences between MF/F 400/10 µg and F 10 µg
of 59 mL, 101 mL, and 82 mL, respectively (P # 0.033).
A significant mean difference of 101 mL was observed
for MF/F 400/10 µg compared with placebo (P , 0.001).
Similarly for MF/F 200/10 µg, a significant mean increase
of 66 mL was observed compared with placebo (P = 0.013).
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Figure 3 Serial FEV1 post-dose at day 1 (A) and week 26 (B).
Notes: Significantly greater increases in FEV1 occurred with both MF/F treatments compared with MF at all time points on day 1 (P , 0.001), as well as week 26 (P # 0.035).
Compared with F 10 µg, MF/F 400/10 µg had significantly greater increases in FEV1 at all time points on week 26 (P # 0.016), whereas MF/F 200/10 µg had significantly greater
increases versus F only at the 4 and 8 hour post-dose time points (P # 0.022).
Abbreviations: BID, twice daily; FEV1, forced expiratory volume in 1 second; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose
combination formulation.
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This supports an overall benefit of both doses of MF/F for
AM pre-dose (trough) FEV1, while the nominally increased
efficacy of MF/F 400/10 µg over MF/F 200/10 µg provides
further evidence of a dose response.
Some subjects had FEV1 measurements long after they
had stopped taking the study treatment. In the second analysis
of AM pre-dose FEV1, performed after database lock and
exclusion of these subjects, statistical significance was
achieved for this co-primary endpoint, with a difference of
58 mL between MF/F 400/10 µg and F 10 µg (P = 0.030),
and a difference of 105 mL between MF/F 400/10 µg and
placebo (P , 0.001).
The co-primary endpoints were analyzed prospectively
in all randomized subjects, and post hoc in a subgroup of
subjects with baseline FEV1 ,50% predicted. The post
hoc analyses were performed to assess treatment effects
in subjects with severe or very severe COPD. At the week
13 endpoint in this subgroup, significant differences in
mean changes from baseline in FEV1 AUC0–12 h occurred,
with a difference of 101 mL between MF/F 400/10 µg and
MF 400 µg (P , 0.001), 88 mL between MF/F 200/10 µg
and MF 400 µg (P , 0.001), and 83 mL between F
10 µg and placebo (P = 0.001). Also at the week 13 endpoint, the mean change from baseline in AM pre-dose
(trough) FEV1 was 18 mL greater with MF/F 400/10 µg
compared with F 10 µg, although the difference was not
significant.

Key secondary efficacy variables
Reported here are changes from baseline in the SGRQ total
score. The mean reductions in SGRQ total score at the week
26 endpoint in the MF/F 400/10 µg and placebo groups were
6.04 and 2.88 points, respectively. The difference between
these treatments (3.16) was significant (P = 0.020). Also
at the week 26 endpoint, the MF/F 200/10 µg group had a
mean reduction in SGRQ total score of 7.99 points, with a
significant difference (5.11; P , 0.001) from placebo. Both
MF/F treatments achieved improvements versus baseline,
which surpassed the MCID threshold of greater than a
four-unit improvement. The changes from baseline with MF
400 µg (5.87) and F 10 µg (4.93) also surpassed the MCID
(Figure 5).
The proportion of COPD symptom-free nights over
26 weeks of treatment was highest in the MF/F 200/10 µg
group (17%) and lowest in the placebo group (12%). The
MF/F 400/10 µg, MF 400 µg, and F 10 µg groups had proportions of 13%, 16%, and 13%, respectively. Comparisons
of these treatment differences were not statistically significant. The proportion of subjects with partly stable COPD at
week 26 ranged from 37.5% to 43.0% across the treatment
groups.
The proportions of subjects who experienced mild,
moderate, or severe COPD exacerbations across the
26-week treatment period in the MF/F 400/10 µg, MF/F
200/10 µg, MF 400 µg, F 10 µg, and placebo groups were

∆ = 49 mL; P = 0.062
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∆ = 70 mL; P = 0.008
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Figure 4 AM pre-dose (trough) FEV1 at week 13 endpoint.
Abbreviations: AM, morning; BID, twice daily; FEV1, forced expiratory volume in 1 second; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol
fixed-dose combination formulation.
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37.6%, 32.3%, 33.3%, 40.2%, and 45.7%, respectively. The
proportion was significantly lower than placebo for MF/F
400/10 µg (P , 0.027), as well as for MF/F 200/10 µg
and MF 400 µg (P , 0.001 and P = 0.003, respectively).
In the active treatment groups, the median time to first
exacerbation was beyond the 26-week treatment period.
Based on the log-rank test for equality of survival curves,
MF/F 400/10 µg, MF/F 200/10 µg, and MF 400 µg were
superior to placebo (P # 0.027) for all randomized subjects.
Similar results were observed for time to first exacerbation
in smokers and ex-smokers, for whom log-rank testing of
survival curves found MF/F 400/10 µg was superior to
placebo (P = 0.027).
The majority of first COPD exacerbations were mild
exacerbations (283/444; 64%). Some subjects on active
treatment who experienced a mild exacerbation continued
in the study and experienced a moderate or severe exacerbation later on. Therefore, an additional analysis of time
to first exacerbation evaluated only subjects whose first
event was a moderate or severe exacerbation (Figure 6).
The placebo group had the highest proportion of subjects
reporting moderate or severe COPD exacerbations as their
first event (24.6%). The proportions of subjects with moderate or severe first exacerbations in the MF/F 400/10 µg,
MF/F 200/10 µg, MF 400 µg, and F 10 µg groups were
15.4%, 12.8%, 16.9%, and 18.4%, respectively. Both MF/F
groups were superior to placebo (P # 0.006), providing
evidence of the effectiveness of both dose levels of MF/F
in reducing the incidence of moderate or severe COPD
exacerbations.

Change from baseline in
total SGRQ score, LS mean

0

MF/F
400/10 µg
BID

MF/F
200/10 µg
BID

Safety

Treatment-emergent adverse events
Both MF/F combination doses were well tolerated during the
26-week treatment period. The overall incidence of treatmentemergent AEs was similar across the treatment groups,
ranging from 33.5% for MF/F 200/10 µg to 44.4% for MF/F
400/10 µg (Table 2). The percentage of subjects reporting
pneumonia (including the AE terms of pneumonia, pneumonia viral, pneumonia aspiration, and lobar pneumonia) during
the treatment period was 1.8% overall, and ranged from 0.8%
to 3.1% across all treatment groups. If COPD exacerbation
met the criteria for a serious AE (eg, was life-threatening,
required hospitalization, or prolonged hospitalization), it
was recorded as an AE. Serious AEs occurred in 96 subjects
(8.0%) during the treatment period, with numbers ranging
from 6.7% to 8.9% across groups. A total of 20 subjects
(1.7%) had serious AEs considered life-threatening, with
numbers similar across all five groups. Overall, 52 subjects
(4.3%) discontinued from treatment due to adverse events. A
total of 15 (1.3%) subjects died during the treatment period
across the five groups; most cases were related to cardiopulmonary events and all were considered unlikely to be related
to the study drug. The most commonly reported treatmentemergent AEs during the treatment period were headache
(4.4% overall), nasopharyngitis (3.6% overall), upper respiratory tract infection (3.3% overall), COPD (3.1% overall), and
hypertension (2.8% overall) (Table 3). During the 52-week
study period, the incidence of treatment-emergent AEs in
the active treatment groups ranged from 44.4% for MF/F
200/10 µg to 51.1% for MF/F 400/10 µg (Table 2).

MF
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F 10 µg
BID

Placebo
BID
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∆ = 5.11, P < 0.001

Figure 5 SGRQ total score change from baseline at week 26 endpoint.
Notes: Compared with placebo, significantly greater improvements in SGRQ total scores occurred with MF/F 400/10 µg (P = 0.020) and MF 400 µg (P = 0.023), as well as
with MF/F 200/10 µg. The difference between MF/F 200/10 µg and F 10 µg was also significant (P = 0.020) at the week 26 endpoint.
Abbreviations: BID, twice daily; SGRQ, St George’s Respiratory Questionnaire; FEV1, forced expiratory volume in 1 second; F, formoterol; MF, mometasone furoate; MF/F,
mometasone furoate/formoterol fixed-dose combination formulation.
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Treatment-related adverse events
Overall, 90 subjects (7.5%) reported a treatment-related
AE, the most frequent of which were lenticular opacities
(1 subject MF/F 200/10 µg, 1 subject MF/F 400/10 µg,
2 subjects MF 400 µg, 3 subjects F 10 µg, and 1 subject
placebo), dysphonia (2 subjects MF/F 200/10 µg, 1 subject
MF/F 400/10 µg, 4 subjects MF 400 µg, and 1 subject
placebo), and oral candidiasis, including the AE terms
of oral candidiasis, oropharyngeal candidiasis, and oral
fungal infection (1 subject MF/F 200/10 µg, 2 subjects
MF/F 400/10 µg, 6 subjects MF 400 µg, and 1 subject
F 10 µg).

Safety extension
During the 26-week safety extension, the AEs reported
by $2% of subjects in the active treatment groups were
upper respiratory tract infection, nasopharyngitis, headache,
COPD, bronchitis, influenza, arthralgia, lenticular opacities,
hypertension, and back pain (Table 4). During the entire study
period (treatment period plus safety extension), 23 subjects
(2.4%) reported pneumonia (including the AE terms of pneumonia, pneumonia viral, pneumonia aspiration, and lobar
pneumonia) across the four active treatment groups. Thirteen

of the 26 events in these 23 subjects were considered to be
severe, and all of the events were considered to be unrelated
to the study drug.

Systemic and ocular effects
No clinically meaningful electrocardiographic changes were
observed during the study period, with the exception of three
subjects (one in the MF/F 400/10 µg group, one in the MF
400 µg group, and one in the placebo group) who had corrected QT interval increases from baseline. Study treatments
had minimal effects on the HPA axis and on BMD, as measured at selected centers over the study period. The treatment
groups were well-balanced with regard to baseline 24-hour
plasma cortisol (range: 188.9–215.4 µg/dL · hour), and small,
insignificant decreases in plasma cortisol were seen across
all active treatment groups at weeks 26 and 52. For BMD
in the lumbar spine (LS) – the region of greatest interest –
decreases in BMD were ,2% across all treatment groups at
weeks 26 and 52. The greatest loss of LS-BMD was 1.2%
in the MF 400 µg group at week 26. The MF/F 200/10 µg
group had a slight increase in LS-BMD (0.6%) at week 26,
which was significant compared with the MF/F 400/10 µg
(−0.9%, P = 0.035), MF 400 µg (-1.2%, P = 0.036), and
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Figure 6 Time to first moderate or severe exacerbation over the 26-week treatment period.
Notes: *P , 0.001 versus placebo; †P = 0.027 versus placebo; ‡P = 0.003 versus placebo.
Abbreviations: F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination formulation.
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Table 2 Summary of treatment-emergent adverse events
Number of subjects (%)
MF/F 400/10 μg BID
(n = 225)
Treatment period (weeks 1–26)
Any AE
100 (44.4)
Treatment-related AE
19 (8.4)
Severe or life-threatening AE
18 (8.0)
Life-threatening AE
6 (2.7)
Serious AE
19 (8.4)
Discontinuation due to AE
12 (5.3)
Death
4 (1.8)
Treatment period + safety extension (weeks 1–52)
Any AE
115 (51.1)
Treatment-related AE
22 (9.8)
Severe or life-threatening AE
23 (10.2)
Life-threatening AE
7 (3.1)
Serious AE
26 (11.6)
Discontinuation due to AE
17 (7.6)
Death
6 (2.7)

MF/F 200/10 μg BID
(n = 239)

MF 400 μg BID
(n = 253)

F 10 μg BID
(n = 243)

Placebo BID
(n = 236)

80 (33.5)
13 (5.4)
15 (6.3)
4 (1.7)
16 (6.7)
6 (2.5)
2 (0.8)

94 (37.2)
25 (9.9)
10 (4.0)
3 (1.2)
21 (8.3)
7 (2.8)
3 (1.2)

93 (38.3)
19 (7.8)
15 (6.2)
4 (1.6)
19 (7.8)
14 (5.8)
4 (1.6)

95 (40.3)
14 (5.9)
12 (5.1)
3 (1.3)
21 (8.9)
13 (5.5)
2 (0.8)

106 (44.4)
19 (7.9)
19 (7.9)
6 (2.5)
28 (11.7)
12 (5.0)
2 (0.8)

113 (44.7)
32 (12.6)
20 (7.9)
6 (2.4)
33 (13.0)
17 (6.7)
5 (2.0)

112 (46.1)
20 (8.2)
19 (7.8)
6 (2.5)
25 (10.3)
15 (6.2)
6 (2.5)

Abbreviations: AE, adverse event; BID, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination formulation.

placebo (−0.007, P = 0.030) groups. Only six subjects had
LS-BMD loss .6% during the study period: two subjects
each in the MF/F 400/10 µg and MF 400 µg groups, one
subject in the MF/F 200/10 µg group, and one subject in the
F 10 µg group.
Ophthalmologic examinations found that between 5.0%
(MF/F 200/10 µg) and 7.5% (MF 400 µg) of subjects had
LOCS III increases of $1 unit over the 52-week study period.
Four MF/F 200/10 µg subjects and two MF 400 µg subjects

reported cataracts and were discontinued from the study, as
per protocol. Additionally, intraocular pressure $22 mmHg
was reported for 14 subjects at week 26, and six subjects at
week 52.

Discussion

Treatment for 26 weeks with MF/F 400/10 µg BID and
200/10 µg BID significantly improved lung function and
was well tolerated in subjects with moderate-to-very severe

Table 3 Treatment-emergent adverse events in $2% of subjects in any treatment group
Number of subjects (%)

Headache
Upper respiratory tract infection
COPD*
Nasopharyngitis
Hypertension
Influenza
Pneumonia
Bronchitis
Pyrexia
Back pain
Peripheral edema
Cough
Dysphonia

MF/F 400/10 μg BID
(n = 225)

MF/F 200/10 μg BID
(n = 239)

MF 400 μg BID
(n = 253)

F 10 μg BID
(n = 243)

Placebo BID
(n = 236)

8 (3.6)
10 (4.4)
10 (4.4)
9 (4.0)
5 (2.2)
3 (1.3)
7 (3.1)
5 (2.2)
5 (2.2)
3 (1.3)
2 (0.9)
1 (0.4)
2 (0.9)

7 (2.9)
6 (2.5)
4 (1.7)
5 (2.1)
9 (3.8)
8 (3.3)
4 (1.7)
3 (1.3)
1 (0.4)
3 (1.3)
2 (0.8)
4 (1.7)
2 (0.8)

13 (5.1)
6 (2.4)
6 (2.4)
10 (4.0)
6 (2.4)
6 (2.4)
5 (2.0)
1 (0.4)
5 (2.0)
4 (1.6)
1 (0.4)
5 (2.0)
5 (2.0)

11 (4.5)
7 (2.9)
5 (2.1)
10 (4.1)
10 (4.1)
3 (1.2)
4 (1.6)
6 (2.5)
0
5 (2.1)
5 (2.1)
2 (0.8)
0

14 (5.9)
11 (4.7)
12 (5.1)
9 (3.8)
3 (1.3)
5 (2.1)
2 (0.8)
1 (0.4)
3 (1.3)
5 (2.1)
1 (0.4)
1 (0.4)
1 (0.4)

Note: *If COPD exacerbation met criteria for a severe adverse event (eg, was life-threatening, required hospitalization, or prolonged hospitalization), it was recorded as
an adverse event.
Abbreviations: BID, twice daily; COPD, chronic obstructive pulmonary disease; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose
combination formulation.
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Table 4 Treatment-emergent adverse events in $2% of subjects in any active treatment group over the safety extension
Number of subjects (%)

Headache
Upper respiratory tract infection
Nasopharyngitis
Bronchitis
Influenza
COPD*
Hypertension
Back pain
Arthralgia
Lenticular opacities

MF/F 400/10 μg BID
(n = 145)

MF/F 200/10 μg BID
(n = 153)

MF 400 μg BID
(n = 149)

F 10 μg BID
(n = 148)

1 (0.7)
9 (6.2)
5 (3.4)
0
0
2 (1.4)
0
2 (1.4)
3 (2.1)
3 (2.1)

6 (3.9)
4 (2.6)
5 (3.3)
2 (1.3)
2 (1.3)
4 (2.6)
2 (1.3)
0
4 (2.6)
3 (2.0)

3 (2.0)
2 (1.3)
7 (4.7)
1 (0.7)
3 (2.0)
5 (3.4)
3 (2.0)
1 (0.7)
0
0

2 (1.4)
5 (3.4)
2 (1.4)
3 (2.0)
2 (1.4)
3 (2.0)
0
3 (2.0)
0
1 (0.7)

Note: *If COPD exacerbation met criteria for a severe adverse event (eg, was life-threatening, required hospitalization, or prolonged hospitalization), it was recorded as
an adverse event.
Abbreviations: BID, twice daily; COPD, chronic obstructive pulmonary disease; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose
combination formulation.

COPD. In addition, both MF/F treatments significantly
improved respiratory health status as measured by changes
from baseline in SGRQ total scores. The magnitude of these
changes for both MF/F treatments achieved the threshold
for MCID of greater than a four unit improvement from
baseline. Also, subjects treated with MF/F experienced significant reductions in the incidence of moderate or severe
COPD exacerbations over the 26-week treatment period.
The comparatively greater efficacy of MF/F 400/10 µg over
MF/F 200/10 µg on lung function suggests a possible doseresponse effect of the MF component in the MF/F combination formulation.
Based on 12-hour serial spirometry measurements,
MF/F treatment showed a rapid onset of bronchodilation, driven by the F component. The MF/F groups had
increases in FEV1 of about 10% at 5 minutes post-dose
on day 1, and increases .15% at 5 minutes post-dose at
week 26. The latter result shows that the bronchodilator
effect of F was maintained over the 26-week treatment
period, with no evidence of tachyphylaxis. Furthermore, the
12-hour period for serial spirometry in this study was substantially longer than the 1- or 2-hour serial spirometry assessments in some pivotal trials of other ICS/LABA FDCs,8,9,11
although a recent trial of budesonide/formoterol included
serial spirometry data that extended for 12 hours.30
Clinical trials of pharmacotherapy for COPD may
fail to show an improvement in SGRQ that meets the
four unit MCID for total score.11,14 In the present multicenter trial, both MF/F groups had mean improvements
from baseline .4 units, achieving the protocol-defined
MCID, while differences from placebo ranged from 3.16
to 5.11 units. The trial demonstrated a clinically relevant
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improvement in respiratory health status compared with
placebo at week 13 and at endpoint.
The probability of a COPD exacerbation was reduced
with both MF/F combinations. The MF/F 400/10 µg group
had a 17.7% relative risk reduction for mild, moderate, or
severe exacerbations, compared with placebo, whereas the
MF/F 200/10 µg group had a 29.3% relative risk reduction
for these COPD exacerbations. When only the more clinically meaningful moderate or severe COPD exacerbations
were analyzed, MF/F 400/10 µg showed a 37.4% relative risk
reduction for a moderate or severe exacerbation, whereas
MF/F 200/10 µg had a 48.0% relative risk reduction for a
moderate or severe exacerbation. MF/F 400/10 µg showed
a statistically significant reduction in moderate and severe
exacerbations compared not only to placebo but also to MF
and F alone. This occurred despite the fact that the treatment period was only 6 months, a time period over which,
historically, it has been difficult to show significant effects
on exacerbations with pharmacotherapy.
All four active treatments were well tolerated, and there
were no notable differences in the occurrence or nature of
AEs reported for MF/F 400/10 µg compared with MF 400 µg
or F 10 µg alone. The incidence of treatment-emergent
pneumonia was low, and no occurrences of pneumonia
were considered by investigators to be treatment-related.
Regarding systemic safety, effects on HPA axis suppression
were quite modest, and no significant demonstrable adverse
effects on the cardiovascular system, bone mineral density,
lenticular opacities, or intra-ocular pressure occurred in
the subpopulation studied. Longer trials would be needed
to exclude any long-term effects of MF/F on BMD and
ocular safety.
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Smoking is the greatest risk factor for COPD, with
environmental and occupational exposures contributing as
well. Smoking cessation and avoidance of other exposures
is an integral part of COPD prevention and treatment. In the
present study, the MF/F 400/10 µg group had the greatest
proportion of current smokers, as well as a pack-year smoking
history that was up to 36% greater than the other treatment
groups. The ANCOVA model adjusted for this imbalance by
including smoking as a covariate.
The efficacy of an inhaled medication is influenced by
factors that include pharmacodynamic properties, particle
size, and lung deposition of the drug(s) being administered;
the type of inhaler being used (ie, MDI or DPI); as well as
the patient’s inhaler technique.31 With HFA-type MDIs,
the patient inhales deeply and slowly through the mouth
after device actuation to draw medication into the lungs.
Proper hand-breath coordination of device actuation and
inhalation is necessary to ensure that a sufficient dose of
medication is inhaled, and some patients may need to use a
spacer or holding chamber to achieve optimal drug delivery.
No spacers or holding chambers were utilized in this study.
In contrast, drug delivery with a DPI is breath-actuated.
The patient places the inhaler in his or her mouth and takes
a rapid, deep breath to inhale the medication into the lungs.
Deficiencies in a patient’s inhaler technique and treatment
adherence can lead to suboptimal outcomes, and thus
appropriate device selection and attention to patients’ inhaler
acceptance and technique are essential for the successful
management of COPD.32,33

Conclusion
Treatment with MF/F was found to be effective for patients
with moderate-to-very severe COPD, based on improvement
in lung function and health status, as well as reduction in
COPD exacerbations. The MF component was shown to
contribute to the combination, based on AM pre-dose (trough)
FEV1 improvement with MF/F versus F when considering
observed cases across all time points. The F component was
shown to significantly contribute to the combination, based
on FEV1 AUC0–12 h improvement with MF/F versus MF, with
improvements in FEV1 that occur rapidly and are sustained
over time. The two MF/F combination doses evaluated in
this study were well tolerated. Very low rates of pneumonia
occurred in all treatment groups.
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